Galvin Gaustad & Stein LLC Raises Stock Holdings in Zoetis Inc. $ZTS

Galvin Gaustad & Stein LLC raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 6.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,718 shares of the company’s stock after acquiring an additional 3,872 shares during the period. Galvin Gaustad & Stein LLC’s holdings in Zoetis were worth $10,717,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. Sound Income Strategies LLC raised its holdings in Zoetis by 54.3% during the 2nd quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock valued at $67,000 after buying an additional 152 shares during the period. Tandem Investment Advisors Inc. raised its holdings in Zoetis by 100.3% during the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company’s stock valued at $65,140,000 after buying an additional 198,089 shares during the period. Soros Capital Management LLC raised its holdings in Zoetis by 32.0% during the 1st quarter. Soros Capital Management LLC now owns 17,441 shares of the company’s stock valued at $2,872,000 after buying an additional 4,230 shares during the period. Flagship Harbor Advisors LLC raised its holdings in Zoetis by 31.2% during the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company’s stock valued at $1,217,000 after buying an additional 1,760 shares during the period. Finally, Horizon Financial Services LLC purchased a new stake in Zoetis during the 1st quarter valued at $380,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of Zoetis stock opened at $143.32 on Friday. The stock’s fifty day moving average is $149.36 and its two-hundred day moving average is $154.60. The company has a market capitalization of $63.52 billion, a PE ratio of 24.67, a price-to-earnings-growth ratio of 2.30 and a beta of 0.90. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $196.55.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the prior year, the company posted $1.56 EPS. Zoetis’s quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. Zoetis’s dividend payout ratio is presently 34.42%.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday. Piper Sandler increased their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Argus restated a “buy” rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Finally, Stifel Nicolaus lowered Zoetis from a “buy” rating to a “hold” rating and decreased their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Five equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.